The study aimed to identify the usefulness of telemonitoring to detect and manage acute exacerbation of COPD (AECOPD).
Telemonitoring can reduce emergency department (ED) visits and exacerbation-related readmissions, as well as acute exacerbation-related hospital days in chronic obstructive pulmonary disease (COPD), according to a recent analysis out of China.
The results also showed improvements in mortality and the St. George's Respiratory Questionnaire (SGRQ) score.
Acute exacerbation of COPD (AECOPD), where there is an acute worsening of respiratory symptoms affecting health status and lung function, account for the bulk of health care costs related to COPD (about 70%). In AECOPD, patients, many of whom are older, often have difficulty recognizing early signs that the disease is getting worse based on symptoms and cannot respond quickly to manage their health, indicating an urgent need to develop effective options to help patients recognize the early onset of AECOPD.
The authors said they conducted the review and meta-analysis in order to compare the evidence on the effectiveness of telemonitoring in patients with a history of past AECOPD, compared with patients without the intervention.
The authors searched PubMed, Embase, and the Cochrane Library for randomized controlled trials published from 1990 to May 2020. Primary endpoints included ED visits and exacerbation-related readmissions and results were analyzed with multiple regression analysis.
Out of 505 studies, 17 were selected for the final analysis (N = 3001); each included telemonitoring and a control group.
The telemonitoring may have included various forms of telemedicine: telehealthcare, telerehabilitation, teleconsultation, telecare, telehealth, mobile tool, apps, or a call center. The studies also had to include a telemonitoring device to monitor significant parameters or symptoms.
The control group had usual care without the use of any telemonitoring.
Telemonitoring was found to reduce:
SGRQ scores also showed improvement (MD, −3.72; 95% CI, −7.18 to −0.26)
However, telemonitoring did not make a statistically significant difference in all-cause readmissions, the rate of exacerbation-related readmissions, all-cause hospital days, time to first hospital readmission, anxiety and depression, and exercise capacity.
A subgroup analysis by observation period showed that longer periods of telemonitoring (12 months or more) was more effective in reducing readmissions.
Reference
Lu, JW, Wang Y, Sun Y, et al. Effectiveness of telemonitoring for reducing exacerbation occurrence in COPD patients with past exacerbation history: A systematic review and meta-analysis. Front. Med. Published online September 10, 2021. doi: 10.3389/fmed.2021.720019
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
2 Commerce Drive
Cranbury, NJ 08512